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EDITORIAL REVIEW
Digoxin-like inhibitors of active sodium transport and blood
pressure: The current status
More than 30 years ago it was suggested that sodium homeosta-
sis was, in part, attributable to a hormone which could increase
sodium excretion by reducing sodium reabsorption in the
nephron. Early experiments [1] showed that acute volume expan-
sion in the dog was associated with a blood borne substance which
was not aldosterone but which nevertheless increased sodium
excretion in a second, cross-circulated, animal. There followed an
extensive literature demonstrating that volume expansion was
associated with a substance in plasma or urine which decreased
the activity of the sodium transporting enzyme Na/K-ATPase [2],
and it was assumed that the natriuresis of volume expansion was
therefore the result of tubular rejection of sodium through
inhibition of the sodium pump by one natriuretic substance, De
Bold's discovery [3] of the atrial natriuretic factor and the
subsequent observation that this substance does not inhibit active
sodium transport [4] showed that at least two substances had been
involved in the previous investigation, and led to a focus on the
identification of a Na/K-ATPase inhibitor. Many years later we
are still in a position of ignorance concerning the role of this
endogenous inhibitor of active sodium transport. The purpose of
this review is not to detail every advance or reversal in the
attempts at identification of this substance, but to attempt to
explain why progress has been slow, and to highlight the recent
and most interesting observations which have led to endogenous
sodium transport inhibitors being the subject of renewed atten-
tion.
There are some obvious reasons for the intermittent periods of
re-interest in this field, the most overt being the proposal, in the
late seventies and early eighties, that sodium transport inhibitors
could be involved in the etiology of essential hypertension (EHT).
Some of the earliest evidence had suggested a role for a hyper-
tensinogenic substance in the pathogenesis of hypertension in
salt-sensitive rats, probably a low molecular weight stable com-
pound which could be transferred to other animals by parabiosis,
leading to an increase in their blood pressure [5].In 1976 Haddy
and Overbeck [6], finding that the sodium pump was inhibited in
the vasculature of animal models of hypertension, suggested that
the circulating pressor compound might be an inhibitor of the
sodium pump. Blaustein [7] then proposed that inhibition of the
sodium pump might directly increase vascular smooth muscle tone
leading to an increase in peripheral vascular resistance and,
ultimately, de Wardener and MacGregor [8] published a hypoth-
esis in this journal that argued strongly for an important role for
such a factor in the mechanism of EHT, They proposed that a
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hereditary renal defect in the excretion of sodium in EHT results
in the elaboration of a Na/K-ATPase inhibitor with both natri-
uretic and pressor activity. The pressor action would further
encourage natriuresis. This attempt to explain the mechanism of
hypertension provoked extensive experimentation, some of which
suggested that the plasma of patients with EHT reduces active
sodium transport in cells from normotensive individuals [9—13]
and of these studies a number showed a quantitative relationship
between the amount of serum Na/K-ATPase inhibiting activity
and blood pressure in patients with EHT [10, 11, 13].
In parallel with these investigations, and subsequently, a major
effort has been directed toward the identification of the contrib-
utory substance, or, substances. Recent reviewers have made
heroic attempts to summarize this contradictory literature and to
put it in perspective [2, 14—16] and the most confusing aspects
require some explanation. Firstly, the major research effort has
been towards the identification of a sodium transport inhibitor
and the original hypothesis that it should also be natriuretic has
largely been ignored in that few active fractions have been tested
for natriuretic activity. Furthermore, inhibition of the sodium
pump in normal subjects given digoxin does not result in a
natriuresis [17] although cardiac glycosides will cause a natriuresis
when infused selectively into the renal artery at very high concen-
trations [18]. A dissociation between inhibition by endogenous
inhibitory fractions of the sodium pump and natriuresis has clearly
been shown in two studies in which fractions of urine from uremic
patients have been tested for sodium pump inhibition and natri-
uresis in conscious rats [19, 20]. One cannot make any assump-
tions therefore that the many characterized or partially charac-
terized endogenous sodium pump inhibitors will make any
contribution to sodium homeostasis.
Another area of obvious confusion is that the search has not
been confined to the plasma of volume expanded humans, or
indeed patients with EHT. Sodium transport inhibitors (which
have included peptides, steroids and lipids) have been isolated
from innumerable sources, including most organs studied, and
from the serum and urine of normovolemic animals and humans
[2, 14, 15]. Circulating sodium transport inhibitors have also been
reported in states of pathological volume expansion including
uremia [21—24], congestive heart failure [25], following myocardial
infarction [26] and in patients with liver disease [27]. A further
problem lies in the methods used in characterization. Simply
stated, insufficient purification has led to the production of crude
"active fractions" identified by a host of different assays, each with
its own inbuilt potential for non-specificity. This has resulted in
deplorable confusion [14, 15]. Fortunately, this is now widely
appreciated, although some laboratories persist in using inappro-
priate techniques. Lastly, two further areas which expand the
original hypothesis have recently yielded interesting data. These
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include developments concerning the relationship between so-
dium transport and vascular tone, and the suggestion that the
brain may play a fundamental role in the effector pathways of
sodium transport inhibitors or indeed may be a site for their
synthesis.
The assays used: How have they contributed to the confusion?
In the search for an endogenous inhibitor, the measurement of
Na/K-ATPase activity might appear straightforward. The isolated
enzyme is most commonly prepared from dog or rabbit kidney
and is commercially available. However, in view of the heteroge-
neous distribution of the three a isoforms of the enzyme in
different tissues and their variable affinity for cardiac glycosides
[28], the source of enzyme may be more critical than originally
thought. Indeed, the a-2 isoform, which predominates in canine
aorta, is particularly sensitive to ouabain [291. In view of the
interest in the role of endogenous sodium transport inhibitors and
peripheral vascular tone in hypertension, there would therefore
be a strong case for using a vascular smooth muscle preparation of
the enzyme in preference to the enzyme from the kidney which, at
least in the rat, contains only the a-i isoform, known to be
resistant to cardiac glycosides. The methods of measurement of
activity of isolated Na/K-ATPase are well proven, although, as
detailed below, they may be of limited value for detection of
endogenous material. Alternative methods are available includ-
ing: the measurement of sodium efflux [9, 12, 13] or 86Rb
(equivalent to potassium) influx in cells [301; the displacement of
radiolabeled cardiac glycosides from their specific receptor site on
Na/K-ATPase [31]; the short circuit current across toad bladder
[32]; and cross reactivity with antidigoxin antibodies [33]. This
heterogeneity alone is complexing, but is further compounded by
problems specific to the individual assays.
Na/K-A TPase enzyme activity
Na/K-ATPase is a highly complex molecule embedded in the
cell membrane. The enzyme requires many ligands and substrates
for cycling to occur, and for the binding of cardiac glycosides.
Changes in the availability of each of these influence enzyme
activity and can give rise to non-specific inhibition. As it is not
embedded within a cell membrane and lacks the protein buffering
component of the cell membrane [34], the isolated enzyme is
highly susceptible to this form of inhibition and is liable to be
inhibited from both external and cytosolic surfaces [24, 35, 36].
For example, in our laboratory we have found only two adjacent
fractions of human neonatal serum (fractionated by high pressure
liquid chromatography) to inhibit leukocyte sodium transport, yet
nearly all fractions inhibit isolated Na/K-ATPase. The most
commonly used assay of isolated Na/K-ATPase activity [11] in
which ATP generation is linked to the oxidation of NADH
involves two other enzymes, lactate dehydrogenase and pyruvate
dehydrogenase; inhibition of either of these leads to a false
suggestion of Na/K-ATPase inhibition. The assay is normally
carried out with saturating concentrations of ATP which in vivo
might not be the case in many cells. Alternatively, problems could
arise from substantial ATP depletion due to greatly increased
Na/K-ATPase activity or excess pyruvate which reduces NADH
and depletes ATP [23]. Many ions, other than sodium and
potassium, which can inadvertently be concentrated by fraction-
ation techniques, can affect isolated Na/K-ATPase activity includ-
ing protons, magnesium and calcium [37], vanadate [38], and zinc
[39]. Ascorbic acid also inhibits the isolated enzyme [40] by
reducing a group within the ATP binding site, but as this site is on
the inner side of the membrane, this effect is not apparent in
cellular preparations.
Cellular sodium and rubidium transport
Many studies have employed intact cells, particularly erythro-
cytes [9, 41, 42] and leukocytes [9, 11, 13] and more occasionally,
renal tubular cells [43], to test for inhibition of the sodium pump.
Intracellular sodium, or outward fluxes of sodium or inward
transport of 86Rb (as an index of potassium transport) are
measured and the cardiac glycoside sensitive component of the
flux taken to represent activity of the sodium pump. These assays
are much more specific than those using isolated Na/K-ATPase,
but if any compound affects oxidative phosphorylation and there-
fore cellular ATP, or if it has a detergent effect on the cell
membrane, the sodium pump will be inhibited although digitalis
receptor occupation has not occurred. Lipids, particularly nega-
tively charged phospholipids, are an absolute requirement for
ATPase activity [44] and alterations in the lipid environment by
uptake from the extracellular medium may inhibit or stimulate
activity [44—46]. Free fatty acids directly inhibit cellular sodium
transport [47] and isolated Na/K-ATPase [48] but, as detailed
below, inhibition of Na/K-ATPase by lipid containing fractions is
more likely to result from a "detergent" effect and is unlikely to
represent the presence of a specific ligand. Also, in view of the
different distribution of isoenzymes of Na/K-ATPase, the choice
of cell may be all important in determining the response to
circulating inhibitors.
Displacement of radiolabeled cardiac glycosides
This assay might be of particular value in the detection of an
endogenous cardiac glycoside, since an inhibitor competitively
displacing ouabain or digoxin from the binding site on Na/K-
ATPase could theoretically suggest the presence of a natural
ligand. Displacement of 3H-ouabain has been used in the search
for an endogenous ligand in the serum of hypertensive subjects
[31], neonates [30], normal human serum [49], in fractions of
human urine [50, 51], rat brain [52], and bovine adrenal glands
[53]. Disadvantages include detergent activity of impure fractions
and the influence of external potassium concentration (which has
usually been ignored in studies using whole serum) both of which
influence ligand binding. Binding studies involve extensive wash-
ing of the enzyme/cells when the inhibitor may be lost, and
allowance has also to be made for a degree of non-specific binding
which occurs when high concentrations of 3H-ouabain are ex-
posed to Na/K-ATPase.
Cytochemical assay
Some of the earlier work involved in the detection of endog-
enous inhibitors of the sodium pump was based on a cytochemical
assay for inhibition of Na/K-ATPase in sliced guinea pig kidney
and it was shown that the fractions which inhibit Na/K-ATPase by
this method also stimulated glucose-6-phosphate dehydrogenase
(G6PD) [54]. Subsequent work, however, showed that the frac-
tions which cytochemically could be shown to inhibit Na/K-
ATPase and stimulate G6PD in situ neither inhibited isolated
Na/K-ATPase nor demonstrated binding to a digoxin antibody
[19].
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Digoxin radioimmunoassay
Most commercially available digoxin antibodies demonstrate
high affinity for digoxin and will not bind to cardiac glycosides
other than those which are closely related in structure. The
antibodies are generally directed against a specific portion of the
steroid moiety of the digoxin molecule (a discrete area associated
with position 12 on the steroid backbone) [55]. Many groups have
assumed that an endogenous cardiac glycoside should bind to
digoxin antibodies and "endogenous digoxin.-like immunoreactiv-
ity" (EDLI) has frequently been used to detect endogenous
sodium transport inhibitors. Plasma EDLI was first described by
Besch et al [56] following the observation of unexpectedly high
laboratory values for serum digoxin in premature infants receiving
digoxin therapy. EDLI attracted public attention when, in To-
ronto in 1981, very high levels of serum "digoxin" were foundpost
mortem in a number of babies not receiving digoxin therapy, and
a nurse was accused of murder. Fortunately for the defendant it
was eventually recognized that all neonatal serum gave false
positive values for digoxin. EDLI in neonatal serum is often much
greater than serum digoxin in a fully digitalized subject, but is
highly variable depending on the assay used [57]. The serum of the
neonate does inhibit active sodium transport in a biological assay
[30, 58—62] but a relationship between biological activity and
EDLI is found by some [30, 61] and not others [59, 62].
Pregnant women have raised EDLI which increases further in
p gnant women with hypertension [63—65]. Again no relation-
ship between EDLI in pregnancy and activity in a biological assay
has been found despite evidence of a sodium pump inhibitor in
the serum of women with mild gestational hypertension [65].
Some or all of the EDLI in the neonate and pregnant women is
likely to result from non-specific cross reactivity of the antibody
with the high concentrations of steroids known to be elevated in
pregnancy [66, 67], yet not all reports agree that steroids play a
role [30, 62, 63].
Further evidence for a dissociation between EDLI and biolog-
ical activity has been reported in a dialysis dependent patient [22],
in patients with acute myocardial infarction [26], in EHT [11, 121,
in normal human plasma [49, 68], in human urine [50], in plasma
of saline loaded rats [69], and in in vitro studies of a number of
peptides and steroids [70].
The commercially available Fab fragment of the digoxin anti-
body binds cardiac glycosides other than digoxin, and there is
some evidence largely from investigations of endogenous inhibi-
tors in cord blood that it may have affinity for an endogenous
ligand of Na/K-ATPase. Montali, Balzan and Ghione [71] have
used the Fab fragment to partially purify an inhibitor of erythro-
cyte 86Rb uptake from neonatal serum [71]. The antibody frag-
ments were covalently bound to Sepharose and incubated with
serum. Elution with methanol produced a fraction rich in inhibi-
tor. The Fab fragment also reversed the inhibition of the sodium
pump achieved by incubation of normal erythrocytes with serum
from cord blood [72] and has been found to inhibit the pressor
activity of a centrally administered hypothalamic ouabain-like
substance [73] (see below). In addition, Goodlin [74] has found
that infusion of the Fab fragment into one woman with pre-
eclampsia caused a profound fall in the blood pressure, but this
has not been repeated.
The non-specific binding of digoxin antibodies to endogenous
compounds which do not possess cardiac glycoside-like character-
istics has probably contributed more to the confusion in this field
than any other single factor [14]. Indeed in his recent review Goto
et al have deliberately omitted all reference to data achieved using
this assay [15].
Summary
In view of these pitfalls, and in the absence of any ideal assay,
there is now general agreement that any candidate compound for
an endogenous inhibitor of sodium transport should be tried and
tested by a combination of at least two assays, one of them cellular
sodium or rubidium transport [15]. Fortunately, many of the
studies of the last two or three years have adopted this approach.
This, together, with painstaking attempts at complete purification
has at last begun yield to a degree of conformity in the charac-
teristics of a number of compounds, and in some to positive
identification.
Identified endogenous inhibitors of the sodium pump
Lipids
In the 1980s several investigators identified fatty acids as
circulating sodium pump inhibitors. Linoleic acid was shown to be
associated with fractions which inhibited Na/K-ATPase from hog
plasma [75] and boiled human plasma [76], and oleic acid with
fractions from hog [75], bovine [77] and human plasma [76].
There was some physiological corroboration of this as levels of
free fatty acids increase after saline infusion [75, 78]. More
recently, Lichtstein et al [79] have extracted to purity the novel
unstable hydroxy unsaturated fatty acid derivative 11,13-dihy-
droxy-14-octodecanoic acid from bovine serum which inhibits
3H-ouabain binding and microsomal Na/K-ATPase. In vitro stud-
ies clearly show that free fatty acids inhibit cellular sodium
transport and isolated Na/K-ATPase [48, 80], but inhibition may
well be non-specific [81]. All these Na/K-ATPase assays of "active
fractions" or of the lipids themselves have been carried out in the
absence of protein and may be misleading since, in vivo, free fatty
acids are more than 98% protein bound [82] and unlikely to be
"free" for binding to Na/K-ATPase. The addition of albumin
therefore almost eliminates the inhibition of NaIK-ATPase by
free fatty acids and lisophosphatidylcholines [83], and it is consid-
ered unlikely that these lipids will act as circulating modulators of
the sodium pump. Lisophosphatidyl choline [84], a derivative of
lisophosphatidyl choline [85], and a derivative of lisophosphatidyl
serine [86] have also been isolated from active fractions of plasma.
Again, these are unlikely to represent circulating inhibitors of
Na/K-ATPase as the inhibitory activity of lisophosphatidyl choline
disappears in the presence of protein [83].
Ouabain
Some recent very detailed studies indicate that the tissues and
plasma of animals and humans contain the cardiac glycoside,
ouabain.
In 1989, Hamlyn, Harris and Ludens [36] found one discrete
peak of biologically active material isolated from human plasma
of subjects undergoing routine plasmapheresis which inhibited
86Rb uptake in human red cells, isolated Na/K-ATPase and
competed with 3H-ouabain for binding to Na/K-ATPase. The
active peak contained a compound with very high affinity for
Na/K-ATPase—much greater than any known cardiac glycoside
which stabilized the E2P form of Na/K-ATPase in a manner
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analogous to ouabain. It did not bind to digoxin antibodies and
had no inhibitory effect on H,K-ATPase or sarcoplasmic
reticulum Ca-ATPase. Subsequently, the same group [49, 871
introduced two refinements in the preparation including an
enzyme-affinity purification stage which increased the final yield.
A total of 300 liters of human plasma was processed to yield 31 tg
of the pure inhibitor, representing purification on a dry weight
basis of 0.6 billion-fold. The isolated substance was considered to
be the same compound but purer than that obtained in the earlier
study [36], although it did not possess such high affinity for
Na/K-ATPase, being similar to that for ouabain. Using fast atom
bombardment mass spectrometry [88], a single protonated molec-
ular ion with a molecular weight of 585.2 Da was identified.
Together with the elemental composition deduced to be
C29H45012, the characteristics of this compound matched those of
ouabain (585.291 Da). Linked scan tandem mass spectrometry
showed that the spectra of EDLF obtained were found to be
identical to those of ouabain. In addition, the endogenous
"ouabain" bound with high affinity to specific ouabain antibodies
[89]. These antibodies have high specificity for ouabain and low
affinity for other endogenous steroids and give "ouabain" concen-
trations in human plasma of approximately 0.6 to 1.0 nmol/liter.
The therapeutic levels of digoxin range from ito 3 nmol/liter and
as human Na/K-ATPase, at least in the heart, has twice the affinity
for ouabain as for digoxin, the circulating concentrations of
"ouabain" may be sufficient to exert a physiological effect [90].
This is supported by our in vitro studies which have shown that
0.1—10 nmol!liter of ouabain has a significant effect on vascular
function in human resistance arteries [91, 92, see belowl. These
data cannot completely exclude the possibility that the active
compound is an isomer of ouabain, nor confirm that the sugar
moiety is definitely rhamnose, the glycoside element of ouabain.
L-rhamnose is not normally associated with mammals but it can
be synthesized in vitro from glucose by rabbit skin [93] and the
enzymes responsible for its metabolism are present in the adrenal
and pituitary glands [94]. The discovery of a cardiac glycoside such
as ouabain, which has a cis junction in the steroidal ring (CD cis),
rather than the CD trans ring junction, as found in mammalian
endogenous steroid hormones, is completely novel, and Hamlyn's
discovery would doubtless have been met with more universal
acceptance had a CD trans steroid been isolated. LaBella and
colleagues [95} have proposed that a CD trans steroid could fill the
role of an endogenous sodium pump inhibitor as some CD trans
steroids demonstrate very high affinity for the cardiac glycoside
binding site, amongst them a number of synthetic progesterone
derivatives [95, 96].
One of the criticisms often leveled at the discovery of "ouabain"
is that the compound is so unlikely to be synthesized in mammals
that it must be derived from the diet [97j, and a number of dietary
compounds including tea [98] and rat chow [99] do contain
sodium pump inhibitors. Hamlyn and Manunta [90] also have
some evidence that ouabain is present in meat, fish and shellfish
but argue that the "ouabain" isolated from plasma was an
endogenous compound as it was found in patients maintained on
semisynthetic diets for periods of seven days [491, by which time
they calculated that dietary "ouabain" should have been cleared.
Another potential concern lies in the origin of the plasma used
in the isolation of "ouabain." In one publication the origin of the
plasma is detailed to be saline-loaded individuals [491, and in a
second, by Ludens et al, as patients with neuropathies [87].
However, the characterization described by Mathews et al [88]
was carried out with material obtained from the study of Ludens
et a! [87] which on that occasion was described as volume
expanded plasma. It would appear that the patients from whom
plasma was obtained by plasmapheresis were volume expanded
patients with neuropathies, some of whom were normally on
treatment (not including cardiac glycosides).
The adrenal cortex would appear to be the source of "ouabain"
in the rat [100] as adrenalectomy lowers plasma "ouabain."
Consistent with this, cultured human and bovine adrenal cortical
cells have been shown to secrete "ouabain" [49]. Elevated levels
of plasma "ouabain" have been found in two patients with
adrenocortical tumors [90] and in the venous blood of patients
with congestive heart failure [25].
Two other groups have evidence for an endogenous compound
which could be ouabain. Inagami and Tamura [53] isolated a
compound from bovine adrenal which inhibits 86Rb uptake into
human erythrocytes, isolates Na/K-ATPase, and displaces 3H-
ouabain from erythrocytes and binds to highly specific antibodies
to ouabain [15]. Goto et al [101] have isolated two compounds
from human urine, one more polar than the other. The polar
compound is very similar to ouabain in that it inhibits canine
kidney Na/K-ATPase, and 8'Rb uptake by human erythrocytes,
the dose response curves being almost identical to those of
ouabain. This "ouabain" also increases with saline loading [102]
and with elevation of dietary salt intake [103].
Although, Hamlyn's group has identified "ouabain," the imme-
diate question that arises is whether "ouabain" is associated with
volume expansion and/or hypertension. In a study of congestive
heart failure there was a relationship between the cardiac index
and "ouabain" titer, but "ouabain" concentration was inversely
related to the mean arterial pressure and unrelated to left
ventricular filling pressure [25]. An increase in "ouabain" was not
associated with the volume expansion of mineralocorticoid admin-
istration in humans, but was increased in hypertension associated
with hypothyroidism [90]. Earlier studies using a different
"ouabain" radioimmunoassay described elevated "ouabain" like
activity in the serum of patients with EHT [104], but the immu-
noreactivity was later found not to be specific to ouabain and
ascribed to an unstable lipid [105]. Despite the indication in 1991
[49] that "ouabain" was present in human plasma, there is still no
evidence that the concentration of "ouabain" is elevated in EHT.
Digoxin
As mentioned above, Goto et al [1011 have isolated two
compounds from human urine, one of which appears very similar,
if not identical to ouabain. The second, less polar compound has
characteristics remarkably similar to digoxin [106], having identi-
cal characteristics to digoxin by analysis with high pressure liquid
chromatography and thin layer chromatography.
Bufodienolides
Before the identification of "ouabain" in human serum, the
only positive identification of steroids structurally related to
cardiac glycosides in the animal world was in various tissues of the
toad Bufo marinus [1071 and in nuchodorsal glands of a snake
[108]. These compounds, the bufodienolides, have six membered
lactone rings and are potent inhibitors of sodium transport. Very
recently, bufodienolides have been isolated from the lens of the
human eye, obtained from patients with cataracts [109, 110].
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These compounds, 19-norbufalin and its derivatives, inhibit 3H-
ouahain binding and Na/K-ATPase activity. Lichstein has pointed
out that as the synthesis of these steroids from digitalis com-
pounds requires a photo-oxidation step, the bufodienolide may be
the product of endogenous "digoxin" or "ouabain" in the lens
after exposure to ultraviolet radiation 11091.
Endogenous active sodium transport inhibitors and the brain
lhe discussion above has centered on the characterization of
circulating sodium transport inhibitors. There is also sonic recent
evidence that such a substance may be present in the brain and
may have a local action.
Indirect evidence
In the earliest experiments [111, 1121 an anteroventral third
ventricle (AV3V) lesion of the hypothalamus was shown to
prevent the usual rise in the plasma sodium pump inhibitory
activity which follows saline infusion. Hypothalamic cat-
echolaminergic denervation induced by intraventricular injection
of 6-hydroxydopamine or an AV3V lesion prevents hypertension
in the salt-loaded reduced renal mass (RRM) and in salt-loaded
DOCA rats and also prevents the associated increase in sodium
pump inhibitory activity 1113, 114]. Inhibition of the sodium pump
in these early experiments was estimated by Rb uptake into
normal rat tail arteries incubated in the plasma of the experimen-
tal animal. In addition, the administration of hypertonic saline
into the cerebral ventricles of dogs causes a rise in blood pressure
together with a reduction in ouabain-sensitive 86Rb uptake of
branches of the saphenous veins, and of veins from a control
animal incubated in the experimental dogs plasma 1115]. The rise
in intracellular sodium and fall in potassium in certain skeletal
muscles in rats given DOCA + saline also appears to be related to
a circulating inhibitor of Na/K-ATPase controlled by the hypo-
thalamus. Katafuchi et al [116] observed that in a slow tonic
muscle, the soleus muscle, the changes in intracellular sodium and
potassium can be prevented by either denervation of the muscle
or by bilateral lesions of the ventromedial nuclei. In contrast, the
changes in electrolyte content of a fast twitch muscle, the extensor
digitalis longus, are unaffected by denervation but they are
prevented by either an AV3V lesion or bilateral lesions of the
paraventricular nuclei, which implies a hormonally mediated
mechanism. Two studies have suggested that there may be
hormonally induced release of a sodium pump inhibitor in the
brain. The intracisternal administration of pergolyde, a dopamine
receptor agonist, triggers the release of a circulating sodium pump
inhibitor as measured by 86Rb uptake [117] as does the injection
of atrial natriuretic factor (ANF) into the lateral cerebral ventri-
cles [118].
It is also possible that the brain may be responsible for the
pressor effect of a locally produced or circulating sodium pump
inhibitor. The increase in arterial pressure and renal sympathetic
activity induced by the central administration of hypertonic saline
may be prevented by intracerebroventricular pre-injection of
digoxin-specific antibody Fab fragments but not by intravenous
administration of these antibodies [73, 115, 119]. However, this
must be interpreted with caution in the light of the potential lack
of specificity. Huang and Leenan have also studied the effect in
the spontaneously hypertensive rat (SHR) and the WKY rat of
high and low sodium diets upon the rise in blood pressure and
increase in renal nervous sympathetic activity which follows
intracerebroventricular ouabain infusion [120], a response which
appears to be due to the effect of the ouabain on the posterior
hypothalamus 1121]. In the SHR a high sodium diet diminishes
the pressor response and increase in renal sympathetic activity to
ouabain which were unaffected in the WKY rat. They proposed
that the diminished response in the SHR is due to the high sodium
diet having already increased the hypothalamic concentration of
the endogenous ouabain-like substance to a greater extent than in
the WKY [120].
In support of the suggestion that the brain may synthesize a
cardiac glycoside, two digoxin antibodies have been found to bind
to the hypothalamus (predominantly to the paraventricular and
supraoptic nuclei) of the rat, dog and macaque [122—124]. There
is also intense binding in the subfornical organ and the organum
vasculorum laminae terminalis. The latter is of particular rele-
vance in view of its close proximity to the site of the AV3V lesion.
However, no controls were carried out in which the binding of
non-specific IgG was carried out and again the non-specificity of
the digoxin antibodies must be considered. Nevertheless, the
distribution of binding was similar to an antibody raised against
ouabain [125].
Direct evidence from extracts of the hypothalamus
The active substance obtained from the hypothalamus in some
of the earlier investigations had properties compatible with its
being a peptide [126] and a steroid [127]. In keeping with Goto et
al's [128] finding in plasma, Huang et al 173] have some evidence
(subject to the caveat mentioned above) which suggests that the
active substance in the hypothalamus and pituitary may be
digoxin. Intracerebroventricular injection of an impure extract
with an activity equivalent to approximately 1 nimol/liter ouabain
caused an increase in blood pressure and renal sympathetic nerve
activity which was prevented, or considerably diniinished, by an
intracerebroventricular pre-injection of digoxin antibody Fab
fragments.
Haupert has obtained a sodium pump inhibitor from bovine
hypothalamus, the extraction yielding only 750 pmol of material
from 1 kg wet weight of tissue [129, 130]. Activity has been
demonstrated with the coupled enzyme assay, inhibition of
ouabain binding and changes in short circuit current of the toad
urinary bladder. The material is water soluble, has a molecular
weight less than 1000, and its biological activity is lost after
methylation with diazomethane which suggests the presence of a
carboxylic group. The substance has functional resemblance to a
cardiac glycoside as it is positively inotropic and inhibits the
sodium pump in intact renal epithelial cells. However, Haupert et
al believe that it is not ouabain or digoxin as: (a) it does not cross
react with monoclonal and polyclonal antibodies formed against
digoxin; (b) its effect on short circuit current and its inotropic
action are rapidly reversible; (c) unlike ouabain it traverses
liposomal membranes (but digoxin does); (d) it inhibits sarcoplas-
mic Ca ATPase, perhaps because of (c); (e) it does not promote
phosphorylation of the active site of Na/K-ATPase; and (f) its
ionic requirements for optimal inhibition of Na/K-ATPase activity
differs from ouabain. A recent study [131] provides chromato-
graphic and spectroscopic evidence that this hypothalmic sub-
stance is an isomer of ouabain. It is presumed that the structural
difference between these two substances accounts for their differ-
ent biological properties.
Ferrandi et al [132] have also extracted a hypothalamic pump
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inhibitor from Milan hypertensive (MHS) and normotensive
(MNS) rat strains and from the ox. Using the same procedure,
they have also obtained an extract from the bovine adrenal. The
active substance was identified using the coupled enzyme Na/K-
ATPase assay, 32P-ATP hydrolysis by ouabain binding, and with
erythrocyte 86Rb uptake. Rat and bovine material have the same
functional characteristics. The yield from the MHS hypothalamus
was about 50x greater than from the MNS and provides the first
demonstration of a quantitative relationship between hyperten-
sion and a brain-derived ouabain-like sodium pump inhibitor.
Activity was also found in the MHS rat but not in the MNS rat
adrenal gland. The active material has similarities to ouabain but
in common with Haupert's material, it shows no apparent optical
peak of UV absorbance recorded at 214 nm (the wavelength of
absorbance of ouabain) possibly because of the small amount of
material, The only physicochemical difference to ouabain that
Ferrandi et al observed was the partial inactivation with treatment
with 6 N HCI at 110°C for two hours, whereas the activity of
ouabain was unaffected by this short period of exposure to acid.
Ferrandi et al's material has two additional biological differences
from ouabain, The first is a striking difference in affinity for
different preparations of Na/K-ATPase. The hypothalamic mate-
rial has similar potency to ouabain when synaptosomal Na/K-
ATPase is used, but inhibits rat renal Na/K-ATPase with a
potency about 1000X greater than ouabain and may reflect a-i
isoform specificity for the endogenous ligand. The functional
significance is that this endogenous compound if present in
plasma might be natriuretic, in contrast to ouabain (see earlier).
In addition, this peculiarity of the renal a-i isoform of Na/K-
ATPase which makes it more sensitive to the hypothalamic
ouabain-like substance than to ouabain, to which it is very
insensitive [28], appears to change with age for renal Na/K-
ATPase obtained from an adult rat is more sensitive to the
hypothalamic substance than is renal Na/K-ATPase from a young
rat. The effect of exogenous ouabain, however, is unaffected by the
age of the rat from which the renal Na/K-ATPase is obtained.
Using cytochemical techniques we have found a substance in
the hypothalamus and in the urine which inhibits Na/K-ATPase
activity and stimulates G6PD activity [19, 133]. In the amounts
available, however, it cannot be detected by the coupled enzyme
assay of Na/K-ATPase activity and does not affect leukocyte
sodium pump activity. Though apparently not cardiac glycoside-
like, it is interesting nevertheless. The cytochemically detectable
substance transiently inhibits sodium pump activity in the proxi-
mal tubule of the guinea pig kidney with a maximal effect at four
to six minutes and transiently stimulates G6PD activity at two
minutes. The selectivity of these assays is such that no known
mammalian substance has yet been found which acts in this
precise manner. The plasma activity of this substance in normal
human [1331 and the rat [134] rises with an increase in salt intake
and is raised in EHT [54], the SHR [135] the MHS [136] and the
salt-loaded reduced renal mass (RRM) hypertensive rat [136].
The greatest concentration of the substance in the normal rat is in
the hypothalamus where it rises substantially with a high salt
intake [138], but even higher concentrations are found in the
hypothalamus of the SHR [135] and of the RRM hypertensive rat.
The compound has physicochemical properties which suggest that
the active substance is highly reactive and contains a functionality
of the quaternary ammonium or immonium type [139]. The
bioassayable activity of some compounds of this type with the
cytochemical assays mentioned above have revealed a close
similarity to the hypothalamic substance. To date the most potent
of these is the choline analogue di-methyl methylene immonium
ion.
Vascular sodium pump inhibition and possible mechanisms
of hypertension
The recent identification of "ouabain" as a naturally occurring
mammalian hormone has renewed interest as to how inhibition of
sodium transport could lead to an increase of vascular tone in
humans. One hypothesis, that the brain may mediate the pressor
response to a sodium pump inhibitor, has already been discussed.
In this section, evidence for a direct vasoconstrictor effect on the
vasculature following the inhibition of sodium transport is re-
viewed.
To investigate the response to sodium pump inhibition in
vascular smooth muscle, most experimental studies have made use
of cardiac glycosides, such as digoxin and ouabain, and some
derivatives of progesterone, which as mentioned earlier bind
specifically to Na/K-ATPase. Preparations of vascular smooth
muscle have included conduit arteries, resistance arteries and
cultured vascular smooth muscle cells. In general, inhibition of
active sodium transport has lead to vasoconstriction. Although a
definitive unifying mechanism has remained elusive, ultimately
contraction of the actin-myosin apparatus in vascular smooth
muscle cells only requires a rise in free intracellular calcium. The
relative contributions of the neuroeffector junction, vascular
smooth muscle and endothelial cells to the change in vascular
tone remain contentious and the differing sensitivities to sodium
pump inhibition between species make comparison difficult [42].
The neuroeffector junction
Cardiac glycosides may increase the release and reduce the
uptake of norepinephrine by sympathetic nerve endings. The
increased release is probably mediated by both calcium-depen-
dent and calcium-independent pathways [140—143]. Reduced
reuptake results from elevated intracellular sodium which directly
inhibits calcium-independent sodium-dependent pre-synaptic re-
entry of norepinephrine into the nerve ending [144, 145]. These
mechanisms may play a role in the increase in forearm vascular
resistance (measured by venous occlusion plethysmography)
which follows the intra-arterial infusion of ouabain (0.7 Wmin/
100 ml of tissue) as one group has found it to be sensitive to
phentolamine, an a-blocker [146]. However, earlier studies
showed no effect of a-blockade [147, 148] and those of Hulthen et
al [149] who demonstrated no venoarterial difference in norepi-
nephrine concentrations following intra-arterial ouabain infusion.
Drug-induced changes in forearm blood flow, however, may make
the interpretation of such studies difficult. In the organ bath,
phentolamine inhibits neither digoxin-induced contraction of
human conduit arteries and veins [150, 151] nor ouabain-induced
contraction of human subcutaneous resistance arteries [91]. These
studies have used a wide range of concentrations of cardiac
glycosides and are therefore difficult to interpret; however, most
of the neurophysiological investigations suggest that these mech-
anism are important at concentrations of 1 mol/liter or more
which is 1000X higher than those reported for ouabain in human
plasma [49].
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The vascular smooth muscle cell
Depolarization. The sodium pump is electrogenic and contrib-
utes to a varying degree (depending on the cell type) to the resting
membrane potential. Theoretically, inhibition of this pump in
vascular smooth muscle could lead to sufficient depolarization to
promote calcium entry through voltage-sensitive channels which
may be blocked by antagonists such as verapamil, nifedipine and
diltiazem. Robinson et al [148] showed that ouabain increased
forearm vascular resistance but demonstrated that the dilator
response to intra-arterial verapamil was similar whether the
forearm had been treated with ouabain or not implying that
calcium entry through voltage-dependent channels was an un-
likely cause of the increased resistance. In contrast, nifedipine
relaxed digoxin-induced contraction of isolated human conduit
arteries [150, 151] and diltiazem inhibited approximately 50% of
ouabain-induced vasoconstriction of isolated human subcutane-
ous resistance arteries [91]. These apparently conflicting data
suggest that either the degree of depolarization resulting from
sodium pump inhibition may vary between vascular beds, or that
the voltage thresholds of calcium channels in vascular smooth
muscle differ. Inhibition of the sodium pump leading to depolar-
ization may account for the augmented pressor responsiveness to
norepinephrine and angiotensin observed in normal subjects who
have received digoxin [152]. Similarly, ouabain potentiates the
tone of submaximally precontracted human resistance arteries
and rat mesenteric resistance arteries which Aalkjaer and Mul-
vany have suggested is the consequence of further depolarization
[153, 154]. In some vascular smooth muscle preparations, there-
fore, calcium entry through voltage-gated channels cannot fully
explain the increase in tension resulting from inhibition of the
sodium pump. Other mechanisms need to be considered.
Na/Ca exchange. The most elegant and arguably most conten-
tious theory to explain tension development following inhibition
of the sodium pump is dependent upon the consequent increase in
intracellular sodium and the subsequent reduction in the sodium
gradient across the vascular smooth muscle cell membrane. This
has attracted interest in the light of the elevation of intracellular
sodium which has been observed in patients with EHT [155] and
pregnancy-induced hypertension [156, 157].
Early observations in cardiac, neural and vascular smooth
muscle tissue identified the partial dependence of calcium flux on
the transpiasmalemmal sodium gradient [158—160]. It was sug-
gested that this was performed by a discrete mechanism, Na/Ca
exchange, which in the heart has been identified with a unique
carrier protein [161]. The physiological role of this transporter,
shared with Ca-ATPase, is to maintain low levels of free cytoplas-
mic calcium in the vascular smooth muscle cell. It is proposed that
reduction of the transplasmalemmal sodium gradient which re-
sults from sodium pump inhibition may lead to a rise in calcium
entry not only through depolarization but also from the reduction
of sodium-dependent calcium efflux by Na/Ca exchange [162]. In
support of this, incubation of rat aortic rings in ouabain or low
sodium (to reduce the transplasmalemmal sodium gradient) in-
creases the caffeine- and norepinephrine-sensitive calcium stores
sequestered in the sarcoplasmic reticulum [163]. In the continuing
presence of sodium pump inhibition, saturation of this reservoir
leads to raised free intracellular calcium concentration and stim-
ulation of the actin-myosin contractile apparatus, even in the
presence of calcium channel blockade by diltiazem or nitrendipine
[163]. Blaustein postulated that a circulating sodium pump inhib-
itor would similarly reduce the transplasmalemmal sodium gradi-
ent which has been observed in hypertension [155—157] and
therefore increase intracellular calcium leading to a rise in tone
[7]. This novel hypothesis provided an exciting link between
sodium metabolism and hypertension. Further studies have since
suggested that the influx of calcium arising from reduction of the
normal transplasmalemmal sodium gradient may depend on the
initial concentration of intracellular calcium [163, 164]. This
makes Blaustein's theory even more appealing because physiolog-
ical tone of resistance arteries in vivo results from elevated free
cytoplasmic calcium concentration in the vascular smooth muscle
cells.
The acid test of Blaustein's hypothesis must be its applicability
to human tissue. Using human umbilical arteries, Sato and Aoki
[165] found that ouabain at concentrations from 300 nmol/liter
and above evoked a dose-dependent biphasic response, the early
contraction being sensitive to calcium antagonists and the late
phase being dependent on external calcium and blockable by
amiloride. The effect of amiloride was attributable to inhibition of
Na/Ca exchange, but amiloride is non-specific as it also inhibits
Na/H exchange and voltage-dependent calcium channels [166].
Sato and Aoki also found that incubation in low sodium produced
a concentration-dependent, calcium-dependent and verapamil-
independent contraction, highly suggestive of the presence of
Na/Ca exchange [165]. Dependence of ouabain-induced contrac-
tion on external calcium and Na/Ca exchange has also been
suggested in human placental arteries and veins, although again
amiloride was considered to be a specific inhibitor of Na/Ca
exchange [167, 168]. In contrast, digoxin-induced vasoconstriction
of human mesenteric and crural conduit arteries is completely
blocked by nifedipine, which seems to imply no role for Na/Ca
exchange [150, 151]. However, since nifedipine can also block
Na/Ca exchange [169] these results cannot discount a role for
significant Na/Ca exchange in arteries contracted by digoxin.
Peripheral vascular resistance is determined by the tone of
resistance arteries with diameters in the range of 4 to 400 m
[170] and for Blaustein's hypothesis to have credence, Na/Ca
exchange must be present in vascular smooth muscle cells from
these blood vessels. In the 1980s, Mulvany's group provided
compelling evidence that neither reduction of the transplasma-
lemmal sodium gradient by Na/K-ATPase inhibition with ouabain
nor incubation in low sodium solution (nor both together) raised
the tone of resting isolated rat mesenteric resistance arteries
[171]. The implication being that Na/Ca exchange is not an
important transporter in small arteries [172]. We have shown,
however, that incubation of human subcutaneous resistance ar-
teries in either ouabain at a concentration of 10 nmol/liter and
above or low sodium will cause concentration-dependent constric-
tion which persists in the presence of diltiazem [91]. We have also
found in these small human arteries that low extracellular sodium
concentration will elevate free intracellular calcium concentration
[173]. It may reasonably be argued that the resting resistance
artery is a poor model of the situation in vivo when arteries do
have some intrinsic tone, but, ouabain also potentiates the tone of
submaximally precontracted human [91] and rat [153] resistance
arteries. The precise mechanism for the increase in tone in the
submaximally precontracted arteries may include a role for cal-
cium influx through potential-dependent channels following
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ouabain-induced depolarization but reverse mode Na/Ca ex-
change (that is, Na out, Ca2 in) cannot be discounted [163,
164].
The endothelial cell
The discovery of the endothelial cell layer as a source of potent
vasoconstrictor and vasodilator substances has lead to its recog-
nition as an important determinant of vasomotor tone. Endothe-
hum-derived relaxing factor or nitric oxide (NO) is synthesized
enzymatically from L-arginine by a calcium and NADPH depen-
dent enzyme [174]. Using inactive analogues of L-arginine which
block the synthesis of NO, it has been demonstrated that tonic
release of NO from endothelial cells maintains the circulation of
experimental animals [175] and the human forearm [176] in a
state of active vasodilation. Ouabain inhibits endothelium-depen-
dent relaxation in canine femoral arteries [177] and rat aorta
[178], but has no effect on canine coronary [179, 180] or rabbit ear
arteries [181]. In isolated human subcutaneous resistance arteries,
we found that ouabain in concentrations of 100 pmol/liter and
above caused concentration-dependent inhibition of endotheli-
urn-dependent relaxation [92], but interestingly had no effect on
relaxation induced by sodium nitroprusside, a NO donor. Our
results imply that sodium pump inhibition affects synthesis or
release of NO. To our surprise, however, using forearm venous
plethysmography, ouabain did not inhibit endothelium-dependent
vasodilation induced by carbachol or bradykinin [182] though, as
expected, endothelium-independent vasodilation by sodium nitro-
prusside was unaffected [147, 183]. The explanation for the
discrepancy between our in vitro and in vivo findings remains
uncertain but may either be due to a relative increase in the local
concentration of the infused vasodilator resulting from ouabain-
induced reduction in forearm blood flow or, alternatively, may
reflect differences in Na/K-ATPase sensitivity to ouabain between
the endothelial cells of skeletal muscle and subcutaneous vascular
beds.
Endothelial cells also produce endothelin, a highly potent
vasoconstricting peptide which has been implicated as a determi-
nant of blood pressure [183], although the correlation may only
reflect end organ damage. A physiological role for endothelin
remains to be identified but incubation of cultured bovine pulmo-
nary endothelial cells in a fraction of human urine with sodium
pump inhibitory activity gave rise to a dose-dependent increase in
endothelin secretion which was not seen with ouabain [184]. More
recently, Badr's group [185] has demonstrated increased endothe-
lin production and target cell response in tissue from Dahl-S rats
exposed to ouabain as opposed to Dahl-R rats. Thus, once again
endogenous sodium pump inhibitory activity has been implicated
in the development of hypertension in Dahl-S rats [5]. It will be
interesting to see whether a relationship between endogenous
sodium pump inhibitory activity and endothelin levels can be
established in EHT.
Effect of endogenous "ouabain" and "digoxin" on vascular
contractility
Comprehensive investigation of the vasoreactivity of the two
candidate Na/K-ATPase inhibitors isolated from human urine
[50] and plasma [49] has not been carried out, largely due to the
small quantities of active material available. Goto's urinary digox-
in-like factor inhibits 86Rb uptake increases calcium influx and
decreases calcium efflux in cultured rat aortic smooth muscle cells
[186]. However, experiments to ascertain the effects of their
compound on vascular contractility were not conducted. In con-
trast, Hamlyn's "ouabain" in high concentration (170 nmol/liter)
augments histamine-induced constriction of guinea pig aortic
rings, but is without effect on resting tone, although experiments
involving prolonged exposure were not carried out. In addition,
"ouabain" causes concentration-dependent (at 85 and 170 nmol/
liter) inotropy in repetitively stimulated atria [187]. Although
prolonged digoxin administration in humans does not lead to a
hypertensive response [152], prolonged ouabain ingestion by rats
has recently been shown to increase blood pressure [90].
Two other lines of indirect evidence suggest a role for cardiac
glycosides in the control of peripheral vascular resistance. A
recent study has shown that the dilator response to intra-arterial
potassium at low concentrations (leading to stimulation of the
sodium pump) is blunted in saline-expanded subjects [188]. This
might imply that salt-loading per Se, perhaps through an endog-
enous sodium pump inhibitor, alters the regulation of vascular
tone. This study is consistent with the conclusions made in some
of the earliest studies in this field [189, 190] which showed a
blunted dilator response to potassium in patients with essential
hypertension. Although never proven to be due to a circulating
sodium pump inhibitor, several early studies have shown that
serum from hypertensive subjects has a constrictor effect on
vascular smooth muscle when compared to that of normotensives
[191—195].
Effect of progesterone derivatives and bufodienolides on
vascularcontractility
Some derivatives of progesterone have been considered as
likely candidates for the endogenous sodium pump inhibitor [95].
Although all inhibit isolated Na/K-ATPase, their functional activ-
ity in whole tissue depends on the configuration of the steroid
nucleus [95]. Planar molecules demonstrate no inotropic or
pressor activity [196, 197], whereas non-planar molecules (same
conformation as cardiac glycosides) are inotropic in the isolated
guinea pig heart [196], potentiate tone of submaximally precon-
tracted human resistance arteries and inhibit endothelium-depen-
dent relaxation [197]. To explain the dissociation between sodium
pump inhibitory activity and lack of inotropy, LaBella et al have
suggested that in addition to their ability to inhibit the sodium
pump, the planar molecules can enter the cell and occupy an
undefined receptor which prevents the usual intracellular accu-
mulation of calcium which accompanies such inhibition [95].
The bufodienolides, which are potent inhibitors of the sodium
pump, have been isolated from various animal [107, 108] and
human tissues [109]. Bufalin, a commercially available bufodieno-
lide, has been shown to block KC1-induced vasodilation, potenti-
ate norepinephrine-induced vasoconstriction, increase blood pres-
sure and cardiac contractility in the anesthetized dog [198] and rat
[199]. Similarly, bufalin in concentrations of 1 nmol/liter and
above potentiates the tone of submaximally precontracted iso-
lated human resistance arteries and inhibits endothelium-depen-
dent relaxation [197].
Conclusion
The evidence presented above demonstrates clearly that this
subject is still very much alive. A change in direction towards the
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identification of an inhibitor of active sodium transport and away
from a natriuretic compound has focused the search. The main
aim must be the identification of an endogenous ligand for the
cardiac glycoside receptor on Na/K-ATPase and that this sub-
stance should inhibit active sodium transport. There is now wide
appreciation of the problems involved in the assays of
Na/K-ATPase activity. As a result, the emphasis has moved to
complete purification and characterization of compounds which
will inhibit Na/K-ATPase in several different assays. The most
exciting development has been that of the positive identification
of "ouabain" and the evidence that ouabain has a pressor action
in human vascular tissue. Disappointingly, more than two years
since the identification of "ouabain," there is still no evidence that
it is elevated in EHT. However, the identification of a compound
very similar to ouabain in the rat hypothalamus and the demon-
stration in one study that it is associated with hypertension,
suggest that a family of ouabain-like cardiac glycosides which may
be implicated in hypertension, exists in mammals. Despite the
positive identification of a number of compounds, there is no
room for complacency and the search for similar substances
should be continued.
The possibility that the hypothalamus may be the source of a
sodium pump inhibitor is of particular interest in the context of
the increasing evidence that introduction of a Na/K-ATPase
inhibitor into the hypothalamus may raise the systemic blood
pressure by a central mechanism, although the effector pathway
remains obscure. We suggest that this is likely to be one of the
most rewarding areas of future research.
Now that there is little doubt that endogenous digoxin-like
inhibitors of sodium transport exist, it is of prime importance that
their physiological and pathophysiological roles are carefully
elucidated. EHT is a disease affecting 10 to 15% of the world's
population and the link between these substances, salt intake and
vascular tone, must be pursued with increasing vigor.
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